Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Nature. 2021 Jun 23;595(7867):438–443. doi: 10.1038/s41586-021-03674-1

Figure 1: Heart failure reversibility with BET inhibition correlates with myofibroblast cell state.

Figure 1:

a. Left ventricle (LV) ejection fraction in indicated groups with treatment and withdrawal of JQ1 (50mg/kg/d). ****p-val=1.46x10−7 for TAC JQ1 vs. TAC JQ1 withdrawn at day 62 (one-way ANOVA with Tukey post hoc test). Sham (n=4), TAC (n=6), TAC JQ1 (n=10), TAC JQ1 withdrawn (n=14). b. scRNA- and ATACseq library generation workflow. c, d. UMAP plot of non-CM cells captured from hearts in (b) colored by cluster (c) and sample identity (d), n=35,551. e. UMAP plot of fibroblasts colored by sample identity, n=13,937. f. Fibroblast Periostin (Postn) expression shown as UMAP feature and violin plots. g. Normalized expression score of the 260 genes increased in TAC vs. Sham across fibroblast samples and associated GO terms (Fisher exact test). h. LV fibrosis in TAC JQ1 (n=4) and TAC JQ1 withdrawn (n=8) mice by picrosirius red staining and quantification. (*p=0.0081, Mann-Whitney with Tukey post hoc test). Bar=250um

a,h Data are shown as means ± SEM.